Author + information
- aDepartment of Medicine, University of Connecticut, Hartford, Connecticut
- bDivision of Cardiovascular Medicine, Department of Medicine, University of Utah, Salt Lake City, Utah
- ↵∗Address for correspondence:
Dr. John J. Ryan, Division of Cardiovascular Medicine, University of Utah Health Science Center, 30 North 1900 East, Room 4A100, Salt Lake City, Utah 84132.
There has been considerable focus on the potential role of nitric oxide (NO) and phosphodiesterase (PDE)-5 inhibition in treating heart failure with preserved ejection fraction (HFpEF). However, the results from studies have been conflicting. In a preclinical study, pre-treatment of diabetic rats with a PDE-5 inhibitor, vardenafil, resulted in a significant decrease in left ventricle stiffness. However, the results from clinical trials have been neutral. In this perspective piece, the authors discuss whether or not it is time to move on from targeting NO and PDE5 for the treatment of HFpEF.
Both authors have reported that they have no relationships relevant to the contents of this paper to disclose.
All authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the JACC: Basic to Translational Science author instructions page.
- Received May 23, 2017.
- Accepted May 23, 2017.
- 2017 The Authors